Position in EXEL
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$17,030
+$3,224 QoQ
Shares Held
313
-0.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#652
of 751 holders
Holding Since
Mar 2024
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cape Investment Advisory, Inc. holds $406,155 across 34 Biotechnology names. EXEL ranks #5 (4.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VKTX |
Viking Therapeutics, Inc.
|
2,430 | $94,794 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
181 | $89,907 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
3,709 | $81,078 | |
| 4 | MDXG |
Mimedx Group, Inc.
|
5,500 | $21,175 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
313 | $17,030 | |
| 6 | ARGX |
Argenx SE
|
12 | $11,132 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
27 | $8,127 | |
| 8 | INSM |
INSMED Inc
|
69 | $7,356 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $17,030 | 313 | Shares | Sole | 2026-07-23 | |
| 2025-12-31 | $13,806 | 315 | Shares | Sole | 2026-02-17 | |
| 2025-06-30 | $2,865 | 65 | Shares | Sole | 2025-08-19 | |
| 2025-03-31 | $2,399 | 65 | Shares | Sole | 2025-05-16 | |
| 2024-12-31 | $3,330 | 100 | Shares | Sole | 2025-02-05 | |
| 2024-09-30 | $2,595 | 100 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $2,247 | 100 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $2,373 | 100 | Shares | Defined | 2024-06-21 | |
| No filing history on record for this holder in this stock. | ||||||